keyword
MENU ▼
Read by QxMD icon Read
search

Factor xa

keyword
https://www.readbyqxmd.com/read/28102773/the-optimal-duration-of-anticoagulant-therapy-after-unprovoked-venous-thromboembolism-still-a-challenging-issue
#1
Giovanna Elmi, Giuseppe Di Pasquale, Raffaele Pesavento
As about 50 % of patients with unprovoked venous thromboembolism (VTE) will develop new episodes after discontinuing therapy, indefinite treatment is suggested in patients with low or moderate bleeding risk. Baseline and post-baseline factors can help clinicians to identify patients at high risk of recurrence, who require extended treatment. Residual vein obstruction and D-dimer assay have been shown to be suitable methods for assessing the risk of VTE recurrences after a first unprovoked VTE. In treatment for VTE the use of direct oral anticoagulants (DOAC) is growing instead of the standard adjusted dose of vitamin K antagonists...
January 19, 2017: VASA. Zeitschrift Für Gefässkrankheiten
https://www.readbyqxmd.com/read/28088315/paris-saponin-induced-autophagy-promotes-breast-cancer-cell-apoptosis-via-the-akt-mtor-signaling-pathway
#2
Zhan-Zhi Xie, Man-Mei Li, Peng-Fei Deng, Sheng Wang, Lei Wang, Xue-Ping Lu, Liu-Bing Hu, Zui Chen, Hui-Yang Jie, Yi-Fei Wang, Xiao-Xiao Liu, Zhong Liu
Paris saponins possess anticancer, anti-inflammatory, and antiviral effects. However, the anticancer effect of Paris saponins has not been well elucidated and the mechanisms underlying the potential function of Paris saponins in cancer therapy are needed to be further identify. In this study, we report that saponin compounds isolated from Paris polyphylla exhibited antitumor activity against breast cancer cell lines, MCF-7 and MDA-MB-231. Paris saponin XA-2 induced apoptosis in both cell lines, as evidenced by the activation of caspases and cleavage of Poly (ADP-ribose) polymerase...
January 11, 2017: Chemico-biological Interactions
https://www.readbyqxmd.com/read/28077507/stroke-and-mortality-risk-in-patients-with-various-patterns-of-atrial-fibrillation-results-from-the-engage-af-timi-48-trial-effective-anticoagulation-with-factor-xa-next-generation-in-atrial-fibrillation-thrombolysis-in-myocardial-infarction-48
#3
Mark S Link, Robert P Giugliano, Christian T Ruff, Benjamin M Scirica, Heikke Huikuri, Ali Oto, Andrea E Crompton, Sabina A Murphy, Hans Lanz, Michele F Mercuri, Elliott M Antman, Eugene Braunwald
BACKGROUND: Whether the pattern of atrial fibrillation (AF) modifies the risk/benefit of anticoagulation is controversial. In ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48), the factor Xa inhibitor edoxaban was noninferior to warfarin in preventing stroke or systemic embolic events and significantly reduced bleeding and cardiovascular mortality. However, detailed analyses by AF pattern have not been reported...
January 2017: Circulation. Arrhythmia and Electrophysiology
https://www.readbyqxmd.com/read/28060970/-evaluation-of-oral-anticoagulation-with-rivaroxaban-in-patients-with-new-onset-non-valvular-atrial-fibrillation
#4
Víctor Neira, Ramón Corbalán, Jaime Pereira, Olga Panes, Bernardita Garayar, Andrés Aizman, Silvana Llevaneras, Luis Villarroel
BACKGROUND: Atrial fibrillation (AF) generates a hypercoagulable state with an increased thrombin generation and raised levels of thrombin-antithrombin complexes, which results in a high risk of stroke and thromboembolism. AIM: To evaluate the anticoagulant effect of rivaroxaban by anti-Xa factor activity and its correlation with thrombin-antithrombin complexes, thrombin generation and prothrombin time in patients newly diagnosed with non-valvular AF. PATIENTS AND METHODS: Prospective study in patients with indication of anticoagulation...
September 2016: Revista Médica de Chile
https://www.readbyqxmd.com/read/28053220/application-of-static-modeling-in-the-prediction-of-in-vivo-drug-drug-interactions-between-rivaroxaban-and-anti-arrhythmic-agents-based-on-in-vitro-inhibition-studies
#5
Eleanor Jing Yi Cheong, Janice Jia Ni Goh, Yanjun Hong, Gopalakrishnan Venkatesan, Yuanjie Liu, Gigi Ngar Chee Chiu, Pipin Kojodjojo, Eric Chun Yong Chan
Rivaroxaban, a direct Factor Xa inhibitor, is indicated for stroke prevention in non-valvular atrial fibrillation (AF). Studies have revealed that the clearance of rivaroxaban is largely attributed to CYP3A4, CYP2J2 metabolism and P-gp efflux pathways. Amiodarone and dronedarone are anti-arrhythmic agents employed in AF management. Amiodarone, dronedarone and their major metabolites, N-desethylamiodarone (NDEA) and N-desbutyldronedarone (NDBD) demonstrate inhibitory effects on CYP3A4 and CYP2J2 with FDA recommended probe substrates...
January 4, 2017: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/28051778/a-potential-antidote-a-prohemostatic-factor-xa-variant-for-reversal-of-direct-oral-anticoagulants
#6
James C Fredenburgh, Jeffrey I Weitz
No abstract text is available yet for this article.
November 11, 2016: Circulation Research
https://www.readbyqxmd.com/read/28042443/differences-between-warfarin-and-new-oral-anticoagulants-in-dental-clinical-practice
#7
REVIEW
M Miranda, L S Martinez, R Franco, V Forte, A Barlattani, P Bollero
The oral anticoagulant therapy is used for the cure and the prevention of thromboembolic diseases. In the last fifty years the warfarin has been considered the oral anticoagulant of choice. However, its use is limited by a narrow therapeutic index and by a complex pharmacodynamics, which requires regular adjustments and monitoring of the dose. Recently, three new oral anticoagulant - dabigatran etexilato (direct thrombin inhibitor), rivaroxaban and apixaban (Xa factor direct inhibitor) - have been approved for use in europe...
July 2016: Oral & Implantology
https://www.readbyqxmd.com/read/28042112/mobile-pump-deep-vein-thrombosis-prophylaxis-just-say-no-to-drugs
#8
J Haynes, R L Barrack, D Nam
AIMS: The purpose of this article was to review the current literature pertaining to the use of mobile compression devices (MCDs) for venous thromboembolism (VTE) following total joint arthroplasty (TJA), and to discuss the results of data from our institution. PATIENTS AND METHODS: Previous studies have illustrated higher rates of post-operative wound complications, re-operation and re-admission with the use of more aggressive anticoagulation regimens, such as warfarin and factor Xa inhibitors...
January 2017: Bone & Joint Journal
https://www.readbyqxmd.com/read/28038749/structure-and-anticoagulant-property-of-a-sulfated-polysaccharide-isolated-from-the-green-seaweed-monostroma-angicava
#9
Na Li, Xue Liu, Xiaoxi He, Shuyao Wang, Sujian Cao, Zheng Xia, Huali Xian, Ling Qin, Wenjun Mao
An anticoagulant-active polysaccharide PF2 was extracted with boiling water from the green seaweed Monostroma angicava, further purified by anion-exchange and size-exclusion chromatography. PF2 was a rhamnan-type sulfated polysaccharide with molecular weight of about 88.1kDa. Results of chemical and spectroscopic analyses demonstrated that PF2 consisted of→3)-α-l-Rhap-(1→ and →2)-α-l-Rhap-(1→residues, with partially branches at C-2 of→3)-α-l-Rhap-(1→residues. Sulfate groups were substituted at C-3 of →2)-α-l-Rhap-(1→ residues...
March 1, 2017: Carbohydrate Polymers
https://www.readbyqxmd.com/read/28032346/mannose-binding-lectin-and-l-ficolin-polymorphisms-in-patients-with-community-acquired-pneumonia-caused-by-intracellular-pathogens
#10
Gijs van Kempen, Sabine Meijvis, Hendrik Endeman, Bart Vlaminckx, Bob Meek, Ben de Jong, Ger T Rijkers, Willem Jan Bos
Community acquired pneumonia (CAP) is the leading infectious disease requiring hospitalisation in the Western World. Genetic variability affecting the host response to infection may play a role in susceptibility and outcome in CAP patients. Mannose binding lectin (MBL) and L-ficolin (L-FCN) are two important activators of the complement system and they can enhance phagocytosis by opsonisation. In a prospective cohort of 505 Dutch CAP patients and 227 controls we studied whether polymorphisms in the MBL (MBL2) and FCN (FCN2) genes influenced susceptibility and outcome...
December 29, 2016: Immunology
https://www.readbyqxmd.com/read/28029411/atrial-fibrillation-and-heart-failure-factors-influencing-the-choice-of-oral-anticoagulant
#11
REVIEW
Louise A E Brown, Christopher J Boos
Atrial fibrillation (AF) and heart failure (HF) frequently coexist. AF is identified in approximately one third of patients with HF and is linked to increased morbidity and mortality than from either condition alone. AF is relatively more common in HF with preserved ejection fraction (HFpEF) than with reduced ejection fraction (HFrEF). Nevertheless, the risk of stroke and systemic embolism (SSE) is significantly increased with both HF types and the absolute risk is heavily influenced by the presence and severity of associated additional stroke risk factors...
September 30, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/28025140/protease-activated-receptor-2-exacerbates-adenine-induced-renal-tubulointerstitial-injury-in-mice
#12
Sakiko Hayashi, Yuji Oe, Tomofumi Fushima, Emiko Sato, Hiroshi Sato, Sadayoshi Ito, Nobuyuki Takahashi
Hypercoagulability is associated with chronic kidney disease (CKD). Tissue factor/factor VIIa complex and factor Xa in the coagulation cascade are known to activate protease-activated receptor 2 (PAR2), and to cause inflammation and tissue injury. Although PAR2 is highly expressed in the kidney, it is unclear whether PAR2 plays a pathogenic role in CKD. To test this, we fed the mice lacking Par2 (F2rl1(-/-)) and wild type (F2rl1(+/+)) mice with adenine diet to induce tubulointerstitial injury, a hallmark of CKD...
December 23, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28017463/monitoring-of-anti-xa-activity-and-factors-related-to-bleeding-events-a-study-in-japanese-patients-with-nonvalvular-atrial-fibrillation-receiving-rivaroxaban
#13
Teruhiro Sakaguchi, Hiroyuki Osanai, Yosuke Murase, Hideki Ishii, Yoshihito Nakashima, Hiroshi Asano, Susumu Suzuki, Mikito Takefuji, Yasuya Inden, Kazuyoshi Sakai, Toyoaki Murohara, Masayoshi Ajioka
BACKGROUND: Anti-Xa activity (AXA) in patients with nonvalvular atrial fibrillation (NVAF) and relationship to bleeding events remains unclear. METHODS: We evaluated AXA in 94 patients at both trough and peak rivaroxaban concentrations. Rivaroxaban dosage was determined according to creatinine clearance (CrCl): 10 and 15mg once daily for patients with CrCl 15-49 and CrCl ≥50mL/min, respectively. AXA value distribution and its association with bleeding events were examined in enrolled subjects...
December 22, 2016: Journal of Cardiology
https://www.readbyqxmd.com/read/28009236/increased-blood-cell-phosphatidylserine-exposure-and-circulating-microparticles-contribute-to-procoagulant-activity-after-carotid-artery-stenting
#14
Lu Zhao, Xiaoming Wu, Yu Si, Zhipeng Yao, Zengxiang Dong, Valerie A Novakovic, Li Guo, Dongxia Tong, He Chen, Yayan Bi, Junjie Kou, Huaizhang Shi, Ye Tian, Shaoshan Hu, Jin Zhou, Jialan Shi
OBJECTIVE Phosphatidylserine (PS) is a major component of the inner leaflet of membrane bilayers. During cell activation or apoptosis, PS is externalized to the outer membrane, providing an important physiological signal necessary for the release of the microparticles (MPs) that are generated through the budding of cellular membranes. MPs express PS and membrane antigens that reflect their cellular origin. PS exposure on the cell surface and the release of MPs provide binding sites for factor Xa and prothrombinase complexes that promote thrombin formation...
December 23, 2016: Journal of Neurosurgery
https://www.readbyqxmd.com/read/28007598/identification-of-acap5-as-a-novel-factor-xa-inhibitor-with-both-direct-and-allosteric-inhibition
#15
Yuanjun Zhu, Yuan Lin, Xiaoyan Liu, Wenhui Hu, Yinye Wang
Ancylostoma caninum anticoagulant peptide 5 (AcAP5) is a potent inhibitor for coagulation factor Xa (FXa). Previous studies show that AcAP5 binds to FXa at the active site, and/or the exosite. The active site-binding contributes to direct blocking of FXa catalytic activity, but the effect of exosite-binding and the underlying mechanism remain unknown. To investigate whether and how the exosite-binding affects FXa function, we prepared several AcAP5 mutants with modifications to the active site-binding or exosite-binding region...
December 19, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28007564/structural-analysis-of-heparin-derived-3-o-sulfated-tetrasaccharides-antithrombin-binding-site-variants
#16
Yin Chen, Lei Lin, Isaac Agyekum, Xing Zhang, Kalib St Ange, Yanlei Yu, Fuming Zhang, Jian Liu, I Jonathan Amster, Robert J Linhardt
Heparin is a polysaccharide that is widely used as an anticoagulant drug. The mechanism for heparin's anticoagulant activity is primarily through its interaction with a serine protease inhibitor, antithrombin III (AT), that enhances its ability to inactivate blood coagulation serine proteases, including thrombin (factor IIa) and factor Xa. The AT-binding site in the heparin is one of the most well-studied carbohydrate-protein binding sites and its structure is the basis for the synthesis of the heparin pentasaccharide drug, fondaparinux...
December 20, 2016: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28007364/factor-eight-inhibitor-bypassing-agent-feiba-for-reversal-of-target-specific-oral-anticoagulants-in-life-threatening-intracranial-bleeding
#17
Gordon Mao, Lauren King, Sarah Young, Richard Kaplan
INTRODUCTION: As increasing number of patients present to emergency departments with life threatening hemorrhages, particularly intracranial hemorrhage on anticoagulation physicians must be cognizant of the limitations of the available reversal options. Based upon the available literature, our institution formulated a reversal algorithm for patients with life-threatening bleeding on factor Xa inhibitors by administering factor eight inhibitor bypassing agent (FEIBA) 20 units/kg. METHODS: A retrospective chart review was performed to include all patients who received FEIBA per institutional protocol...
December 19, 2016: Journal of Emergency Medicine
https://www.readbyqxmd.com/read/28002712/andexanet-alfa-for-factor-xa-inhibitor-reversal
#18
LETTER
Joseph J Shatzel, Molly M Daughety, Thomas G DeLoughery
No abstract text is available yet for this article.
22, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/28002711/andexanet-alfa-for-factor-xa-inhibitor-reversal
#19
LETTER
Stuart J Connolly, C Michael Gibson, Mark Crowther
No abstract text is available yet for this article.
22, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/28002279/inadequate-enoxaparin-dosing-predicts-90-day-venous-thromboembolism-risk-among-plastic-surgery-inpatients-an-examination-of-enoxaparin-pharmcodynamics
#20
Christopher J Pannucci, W Bradford Rockwell, Maureen Ghanem, Kory I Fleming, Arash Momeni, Jayant Agarwal
INTRODUCTION: Evidence-based plastic surgery guidelines support the effectiveness of once daily enoxaparin prophylaxis. Despite prophylaxis, one in 25 highest risk patients has a VTE event. We examined the pharmacodynamics of standard enoxaparin doses in plastic surgery patients to examine whether patient-level factors predict enoxaparin metabolism, whether inadequate enoxaparin dose predicts downstream VTE events, and whether a pharmacist-driven dose adjustment protocol was effective...
December 16, 2016: Plastic and Reconstructive Surgery
keyword
keyword
18932
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"